Rudolf Herbst

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

Ulrike Leiter, Rudolf Stadler, Cornelia Mauch et al. · The Lancet Oncology · 2016 · 684 citations

Surgical Oncology, Medicine, Surgical Pathology +7

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

Lisa Zimmer, Julia Vaübel, Peter Mohr et al. · PLoS ONE · 2015 · 286 citations · Full text

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer, Elisabeth Livingstone, Jessica C. Hassel et al. · The Lancet · 2020 · 238 citations

Surgical Oncology, Oncology, Melanoma +6

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node

Ulrike Leiter, Rudolf Stadler, Cornelia Mauch et al. · Journal of Clinical Oncology · 2019 · 236 citations

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Markus V. Heppt, Lucie Heinzerling, Katharina C. Kähler et al. · European Journal of Cancer · 2017 · 196 citations

Prognostic Factors, Programmed Cell Death-1, Medicine +9